Working… Menu

A Phase 1/2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03604692
Recruitment Status : Active, not recruiting
First Posted : July 27, 2018
Last Update Posted : May 14, 2021
Information provided by (Responsible Party):
Syndax Pharmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : May 1, 2022